

CLAIMS

1. A therapeutic agent comprising a microorganism which has a reduced capacity to grow and replicate in the presence of a microbiostatic substance present in, or introduced to, an environment within a subject to which said microorganism migrates following administration wherein said microorganism is capable of inducing an immune response in said subject, which immune response is directed against an antigen on, or secreted by, the microorganism.
2. The therapeutic agent of Claim 1 wherein the microbiostatic agent is bile salts.
3. The therapeutic agent of Claim 1 or 2 wherein the microorganism is a prokaryote.
4. The therapeutic agent of Claim 3 wherein the microorganism is a member of the Enterobacteriaceae.
5. The therapeutic agent of Claim 4 wherein the microorganism is a *Salmonella* sp.
6. The therapeutic agent of Claim 5 wherein the microorganism is *Salmonella dublin*.
7. The therapeutic agent of Claim 6 wherein the microorganism comprises an insertion or deletion in an *rpoB* gene.
8. The therapeutic agent of Claim 7 wherein the microorganism is selected from N-RM4, N-RM8, N-RM9, N-RM15, N-RM20, N-RM25, N-RM27 and R-NM29.
9. The therapeutic agent of Claim 1 wherein the subject is a mammal.

BEST AVAILABLE COPY

10. The therapeutic agent of Claim 9 wherein the subject is a livestock animal.
11. The therapeutic agent of Claim 10 wherein the livestock animal is selected from the list consisting of a cow, a sheep and a pig.
12. The therapeutic agent of Claim 9 wherein the mammal is a laboratory test animal.
13. The therapeutic agent of Claim 12 wherein the laboratory test animal is selected from the list consisting of a mouse, a rat, a rabbit and a guinea pig.
14. The therapeutic agent of Claim 9 wherein the subject is a human.
15. The therapeutic agent of Claim 1 wherein the microorganism is rendered unable to grow or replicate in the presence of the microbiostatic substance by exposing the microorganism to nalidixic acid and rifampicin or chemical or functional equivalents thereof for a time and under conditions sufficient to induce a metabolic-drift mutation.
16. The therapeutic agent of Claim 1 wherein the antigen is naturally occurring with said microorganism.
17. The therapeutic agent of Claim 1 wherein the antigen is introduced to said microorganism.
18. The therapeutic agent of Claim 1 wherein the microorganism induces a humoral and/or T-cell-mediated immune response.
19. The therapeutic agent of Claim 16 wherein the microorganism induces a mucosal immune response.

20. A therapeutic agent comprising a *Salmonella sp.* which carries a metabolic-drift mutation resulting in a reduced capacity to grow and replicate in the presence of bile salts present in a subject to which the therapeutic agent is administered said *Salmonella sp.* is capable of inducing an immune response against itself or an antigen produced by itself.
21. The therapeutic agent of Claim 20 wherein the *Salmonella sp.* is *Salmonella dublin*.
22. The therapeutic agent of Claim 21 wherein the microorganism comprises an insertion or deletion in an *rpoB* gene.
23. The therapeutic agent of Claim 22 wherein the microorganism is selected from N-RM4, N-RM8, N-RM9, N-RM15, N-RM20, N-RM25, N-RM27 and R-NM29.
24. The therapeutic agent of Claim 21 wherein the subject is a livestock animal.
25. The therapeutic agent of Claim 24 wherein the subject is a cow, a sheep or a pig.
26. The therapeutic agent of Claim 25 wherein the subject is a cow.
27. The therapeutic agent of Claim 20 wherein the immune response is a humoral immune response.
28. The therapeutic agent of Claim 27 wherein the humoral immune response is a mucosal immune response.

29. A method of vaccinating a subject against a microorganism or an antigen produced by a microorganism said method comprising selecting a microorganism, exposing the microorganism to naladixic acid and rifampicin or their chemical or functional equivalents for a time and under conditions sufficient to induce a metabolic drift mutation which renders the microorganism substantially unable to grow or replicate in the presence of a selected microbiostatic agent, and administering said mutated microorganism to the subject under conditions sufficient for the microorganism to migrate to an environment comprising the microbiostatic agent where it maintains itself for a time sufficient for an immune response to be induced to the microorganism or an antigen produced thereby.

30. The method of Claim 29 wherein the microbiostatic agent is bile salts.

31. The method of Claim 29 or 30 wherein the microorganism is a prokaryote.

32. The method of Claim 31 wherein the microorganism is a member of the Enterobacteriaceae.

33. The method of Claim 32 wherein the microorganism is a *Salmonella* sp.

34. The method of Claim 33 wherein the microorganism is *Salmonella dublin*.

35. The therapeutic agent of Claim 34 wherein the microorganism comprises an insertion or deletion in an *rpoB* gene.

36. The therapeutic agent of Claim 35 wherein the microorganism is selected from N-RM4, N-RM8, N-RM9, N-RM15, N-RM20, N-RM25, N-RM27 and R-NM29.

37. The method of Claim 29 wherein the subject is a mammal.
38. The method of Claim 37 wherein the subject is a livestock animal.
39. The method of Claim 38 wherein the livestock animal is selected from a cow, a sheep and a pig.
40. The method of Claim 37 wherein the mammal is a laboratory test animal.
41. The method of Claim 40 wherein the laboratory test animal is selected from the list consisting of a mouse, a rat, a rabbit and a guinea pig.
42. The method of Claim 37 wherein the mammal is a human.
43. The method of Claim 41 wherein the microorganism induces a humoral and/or a T-cell-mediated immune response.
44. The method of Claim 43 wherein the microorganism induces a mucosal immune response.
45. A purified culture of a *Salmonella* sp. comprising cells which have been exposed to naladixic acid and rifampicin or their chemical or functional equivalents under conditions sufficient to induce a metabolic-drift mutation which renders the *Salmonella* sp. substantially incapable of growing or replicating in the presence of bile salts.
46. The purified culture of Claim 45 wherein the *Salmonella* sp. is *Semonella dublin*.

47. The purified culture of Claim 45 or 46 wherein the culture is freeze dried, frozen or reconstituted.

48. Use of the purified culture of Claim 45 or 46 or 42 in the manufacture of a vaccine to induce an immune response in a mammal to a *Salmonella* sp.

- 157 -

CLAIMS

1. A therapeutic agent comprising a live attenuated microorganism produced by selecting from metabolic drift mutants of a wild strain of a microorganism an
5 attenuated microorganism that has a reduced capacity to grow and replicate in the presence of bile salts as compared to the wild strain, wherein the attenuated microorganism is capable of inducing an immune response in the subject to the wild strain.
- 10 2. The therapeutic agent of Claim 1 wherein the attenuated microorganism penetrates an organ selected from liver, spleen and gall bladder after parenteral administration of the therapeutic agent.
3. The therapeutic agent of Claim 1 wherein the attenuated microorganism
15 colonises an organ selected from liver, spleen and gall bladder in lower numbers than the wild strain after parenteral administration.
4. The therapeutic agent of Claim 1 wherein the attenuated microorganism is a member of the Enterobacteriaceae.
- 20 5. The therapeutic agent of Claim 4 wherein the attenuated microorganism is a *Salmonella sp.*
6. The therapeutic agent of Claim 1 wherein the attenuated microorganism is
25 *Salmonella dublin*.
7. The therapeutic agent of Claim 2 wherein the attenuated microorganism comprises a sequence alteration in an *rpoB* gene.
- 30 8. The therapeutic agent of Claim 7 wherein the attenuated microorganism is selected from N-RM4, N-RM8, N-RM9, N-RM15, N-RM20, N-RM25, N-RM27 and R-NM29.

- 158 -

9. The therapeutic agent of Claim 7 wherein the attenuated microorganism is N-RM25.
10. The therapeutic agent of Claim 1 wherein the subject is a livestock animal.
- 5 11. The therapeutic agent of Claim 10 wherein the livestock animal is selected from the list consisting of a cow, a sheep and a pig.
12. The therapeutic agent of Claim 1 wherein the subject is a laboratory test animal.
- 10 13. The therapeutic agent of Claim 12 wherein the laboratory test animal is selected from the list consisting of a mouse, a rat, a rabbit and a guinea pig.
- 15 14. The therapeutic agent of Claim 1 wherein the subject is a human.
15. The therapeutic agent of Claim 1 wherein the metabolic drift mutants are produced by exposing the wild strain to nalidixic acid and rifampicin or chemical or functional equivalents thereof for a time and under conditions sufficient to induce a metabolic-drift mutation.
- 20 16. The therapeutic agent of Claim 1 wherein the immune response is directed to an antigen that is naturally occurring with the microorganism.
- 25 17. The therapeutic agent of Claim 1 wherein the immune response is directed to an antigen that is introduced to the microorganism.
18. The therapeutic agent of Claim 1 wherein the attenuated microorganism induces a humoral and/or T-cell-mediated immune response.
- 30 19. The therapeutic agent of Claim 1 wherein the attenuated microorganism induces a mucosal immune response.

- 159 -

20. The therapeutic agent of Claim 1 wherein the attenuated microorganism is capable of inducing an immune response in the subject to another species of microorganism.
- 5 21. The therapeutic agent of Claim 20 wherein the attenuated microorganism is *Salmonella dublin* is capable of inducing an immune response in the subject to *Salmonella typhimurium*.
- 10 22. A therapeutic agent comprising a live attenuated *Salmonella* species produced by selecting from metabolic drift mutants of a wild strain of a *Salmonella* species an attenuated *Salmonella* species that has a reduced capacity to grow and replicate in the presence of bile salts as compared to the wild strain, wherein the attenuated *Salmonella* species is capable of inducing an immune response to itself or to an antigen produced thereby or to the wild strain.
- 15 23. The therapeutic agent of Claim 22 wherein the *Salmonella* sp. is *Salmonella dublin*.
- 20 24. A method of vaccinating a subject against a microorganism or an antigen produced by a microorganism, the method comprising exposing a wild strain of the microorganism to nalidixic acid and rifampicin or their chemical or functional equivalents for a time and under conditions sufficient to produce metabolic drift mutants of the wild strain, which are resistant to nalidixic acid and rifampicin, and selecting from the metabolic drift mutants an attenuated microorganism that has a reduced capacity to grow and replicate in the presence of bile salts as compared to the wild strain, and administering the attenuated microorganism to the subject under conditions sufficient for the attenuated microorganism to migrate to an environment comprising the bile salts where it maintains itself for a time sufficient to induce an immune response to the microorganism or an antigen produced thereby.
- 25 30 25. A purified culture of a *Salmonella* species as defined in claim 22.

- 160 -

26. The purified culture of Claim 25 wherein the culture is freeze dried, frozen or reconstituted.
- 5 27. Use of the purified culture of Claim 25 or 26 in the manufacture of a vaccine to induce an immune response in a mammal to a *Salmonella* species.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.